Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BioSpaceBridgeBio Pharma plans to file for approval in the third quarter.Rare DiseaseRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) BioSpace BridgeBio Pharma plans to file for approval in the third quarter. Rare Disease Read full story Post navigation Previous: Biogen trims Apellis pipeline and R&D team after $5.6bn takeoverNext: Zymeworks cuts deal to buy Theravance for $929m in cash Related Stories Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026 Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026